glp-1 psoriatic arthritis Glucagon-like peptide-1 (GLP-1) receptor agonists, obesity and psoriasis: diabetes meets dermatology | Diabetologia Which PsO Patients Can Benefit
Description
Table 1, Figure 2), all-cause mortality (12 RCTs
10.1210/en.2011-1795 26 DavidsonJ
Those GLP-1s have been approved by the Food and Drug Administration for weight loss, Cubanski said
26 There are several ways to design around these patents via 505(b)(2): Different Maintenance Doses : If the innovators patent specifies a maintenance dose of about 2.4 mg, a 505(b)(2) applicant might seek approval for a 2.0 mg or 3.0 mg dose supported by independent clinical data
